Botulinum toxin treatment of secretory disorders

Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for s...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2004-03, Vol.19 (S8), p.S137-S141
Main Authors: Naumann, Markus, Jost, Wolfgang
Format: Article
Language:English
Subjects:
Anti-Dyskinesia Agents - therapeutic use
Axilla - innervation
Biological and medical sciences
botulinum toxin
Botulinum Toxins - therapeutic use
focal hyperhidrosis
Hand - innervation
Humans
Hyperhidrosis - drug therapy
hyperlacrimation
Medical sciences
Neurology
Parkinson Disease - drug therapy
Parkinson's disease
Salivary Gland Diseases - drug therapy
sialorrhea
Sialorrhea - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long‐term benefits of this treatment option. © 2004 Movement Disorder Society
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.20067